{"pmid":32425691,"pmcid":"PMC7229942","title":"ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.","text":["ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.","Cytotherapy","Borger, Verena","Weiss, Daniel J","Anderson, Johnathon D","Borras, Francesc E","Bussolati, Benedetta","Carter, David R F","Dominici, Massimo","Falcon-Perez, Juan M","Gimona, Mario","Hill, Andrew F","Hoffman, Andrew M","de Kleijn, Dominique","Levine, Bruce L","Lim, Rebecca","Lotvall, Jan","Mitsialis, S Alex","Monguio-Tortajada, Marta","Muraca, Maurizio","Nieuwland, Rienk","Nowocin, Anna","O'Driscoll, Lorraine","Ortiz, Luis A","Phinney, Donald G","Reischl, Ilona","Rohde, Eva","Sanzenbacher, Ralf","Thery, Clotilde","Toh, Wei Seong","Witwer, Kenneth W","Lim, Sai Kiang","Giebel, Bernd","32425691"],"journal":"Cytotherapy","authors":["Borger, Verena","Weiss, Daniel J","Anderson, Johnathon D","Borras, Francesc E","Bussolati, Benedetta","Carter, David R F","Dominici, Massimo","Falcon-Perez, Juan M","Gimona, Mario","Hill, Andrew F","Hoffman, Andrew M","de Kleijn, Dominique","Levine, Bruce L","Lim, Rebecca","Lotvall, Jan","Mitsialis, S Alex","Monguio-Tortajada, Marta","Muraca, Maurizio","Nieuwland, Rienk","Nowocin, Anna","O'Driscoll, Lorraine","Ortiz, Luis A","Phinney, Donald G","Reischl, Ilona","Rohde, Eva","Sanzenbacher, Ralf","Thery, Clotilde","Toh, Wei Seong","Witwer, Kenneth W","Lim, Sai Kiang","Giebel, Bernd"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425691","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jcyt.2020.05.002","topics":["Treatment"],"weight":1,"_version_":1667252837704269824,"score":9.490897,"similar":[{"pmid":32373992,"title":"MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.","text":["MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.","At present, SARS-Cov-2 is spread all over the world, becoming a serious threat to people's health. SARS-Cov-2 has a strong infection, and the mortality rate of severe patients after infection is high, but there is no effective treatment. Mesenchymal stem cells (MSCs) have anti-inflammatory and immunomodulatory functions, which can reduce the occurrence of cytokine storm syndrome and acute respiratory distress syndrome. At the same time, MSCs can reduce the level of pulmonary fibrosis and enhance tissue injury repair. In this short report, combined with the progress of preclinical and clinical research, we comment the efficacy of MSCs in the treatment of COVID-19.","Eur Rev Med Pharmacol Sci","Wang, X-Y","32373992"],"abstract":["At present, SARS-Cov-2 is spread all over the world, becoming a serious threat to people's health. SARS-Cov-2 has a strong infection, and the mortality rate of severe patients after infection is high, but there is no effective treatment. Mesenchymal stem cells (MSCs) have anti-inflammatory and immunomodulatory functions, which can reduce the occurrence of cytokine storm syndrome and acute respiratory distress syndrome. At the same time, MSCs can reduce the level of pulmonary fibrosis and enhance tissue injury repair. In this short report, combined with the progress of preclinical and clinical research, we comment the efficacy of MSCs in the treatment of COVID-19."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Wang, X-Y"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32373992","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.26355/eurrev_202004_21037","topics":["Treatment"],"weight":1,"_version_":1666138496382795776,"score":50.04885},{"pmid":32371362,"title":"Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients.","text":["Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients.","As an emerging global health challenge, COVID-19 requires international knowledge to reach novel possible therapeutic strategies, especially for intensive-care patients. During the early stages of infection, pneumocytes II are the primary infected cells, harming the respiratory system. We have previous evidence in murine models that MSc's secretome can be used to treat pulmonary injuries induced with bleomycin, due to its content: growth factors, extracellular vesicles, and exosomes. We hypothesize and strongly recommend MSc secretome testing and production, in xenofree conditions, to be used as an alternative approach in SARS-Cov-2 patients in critical conditions.","Med Hypotheses","Deffune, Elenice","Prudenciatti, Arua","Moroz, Andrei","32371362"],"abstract":["As an emerging global health challenge, COVID-19 requires international knowledge to reach novel possible therapeutic strategies, especially for intensive-care patients. During the early stages of infection, pneumocytes II are the primary infected cells, harming the respiratory system. We have previous evidence in murine models that MSc's secretome can be used to treat pulmonary injuries induced with bleomycin, due to its content: growth factors, extracellular vesicles, and exosomes. We hypothesize and strongly recommend MSc secretome testing and production, in xenofree conditions, to be used as an alternative approach in SARS-Cov-2 patients in critical conditions."],"journal":"Med Hypotheses","authors":["Deffune, Elenice","Prudenciatti, Arua","Moroz, Andrei"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371362","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.mehy.2020.109769","keywords":["covid-19","msc secretome","novel strategy"],"e_drugs":["Bleomycin"],"topics":["Treatment"],"weight":1,"_version_":1666138496416350208,"score":42.856773}]}